23:48 , Oct 15, 2018 |  BC Extra  |  Company News

Management tracks: Rhythm, Redpin

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN)....
21:45 , Oct 12, 2018 |  BioCentury  |  Finance

Versant seizes the RNA moment

As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics. Versant co-led Gotham’s $54 million series A...
23:07 , Oct 11, 2018 |  BC Week In Review  |  Financial News

Cancer company Rgenix raises $40M series C

Rgenix Inc. (New York, N.Y.) raised $40 million on Oct. 9 in a series C round led by Lepu Medical. New investors Oceanpine Capital and the corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259)...
04:01 , Oct 10, 2018 |  BC Extra  |  Financial News

Versant-backed Gotham raises $54M series A

Versant Ventures unveiled a move into the RNA metabolism space with an investment in Gotham Therapeutics (New York, N.Y.). Versant co-led a $54 million series A round with Forbion Capital Partners and SR One. Gotham is...
19:27 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Silverback announces series A extension

Cancer and autoimmune company Silverback Therapeutics Inc. (Seattle, Wash.) raised an extension of its series A round on Sept. 19, bringing the round's total to $47.5 million. The round was led by existing investor OrbiMed....
17:37 , Sep 21, 2018 |  BC Week In Review  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator...
16:33 , Sep 21, 2018 |  BC Week In Review  |  Financial News

Biodesy raises $20M in series C, appoints new CEO

Biodesy Inc. (South San Francisco, Calif.) raised $20 million Sept. 10 in a series C round led by new investor Alexandria Venture Investments. Existing investors 5AM Ventures, Pfizer Ventures and Roche Venture Fund also participated...
13:46 , Sep 20, 2018 |  BC Extra  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription 3...
17:29 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Neurological organoid company System1 raises $25M in series A

System1 Biosciences Inc. (San Francisco, Calif.) raised $25 million in a series A round co-led by CRV and Pfizer Ventures. Alexandria Venture Investments, Dolby Family Ventures, Longevity Fund, Riot Ventures, Kinled Holding, Wilmot Ventures, Webb...
17:29 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Epic raises $52M series E

Epic Sciences Inc. (San Diego, Calif.) raised $52 million in a series E round led by Blue Ox Healthcare Partners. Fellow new investors Deerfield Management and Varian Medical Systems Inc. (NYSE:VAR) joined existing investors Altos...